IL309246A - Dosage regimen for TEAD inhibitor - Google Patents
Dosage regimen for TEAD inhibitorInfo
- Publication number
- IL309246A IL309246A IL309246A IL30924623A IL309246A IL 309246 A IL309246 A IL 309246A IL 309246 A IL309246 A IL 309246A IL 30924623 A IL30924623 A IL 30924623A IL 309246 A IL309246 A IL 309246A
- Authority
- IL
- Israel
- Prior art keywords
- dosing regimen
- tead
- inhibitor
- tead inhibitor
- regimen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239506P | 2021-09-01 | 2021-09-01 | |
| PCT/IB2022/058130 WO2023031798A1 (en) | 2021-09-01 | 2022-08-30 | Dosing regimen for a tead inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309246A true IL309246A (en) | 2024-02-01 |
Family
ID=83355146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309246A IL309246A (en) | 2021-09-01 | 2022-08-30 | Dosage regimen for TEAD inhibitor |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240358720A1 (https=) |
| EP (1) | EP4395768A1 (https=) |
| JP (1) | JP2024532325A (https=) |
| KR (1) | KR20240055021A (https=) |
| CN (1) | CN117835977A (https=) |
| AU (1) | AU2022340987A1 (https=) |
| CA (1) | CA3225444A1 (https=) |
| IL (1) | IL309246A (https=) |
| MX (1) | MX2024002566A (https=) |
| TW (1) | TW202327579A (https=) |
| WO (1) | WO2023031798A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3156404A1 (en) * | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| EP4030233B1 (en) | 2019-09-18 | 2025-05-07 | Ningbo Sunny Opotech Co., Ltd. | Periscopic camera module and electronic device |
| UY39129A (es) | 2020-03-16 | 2021-10-29 | Novartis Ag | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |
| CA3205726A1 (en) | 2021-01-25 | 2022-07-28 | Alfredo C. Castro | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
-
2022
- 2022-08-30 US US18/687,599 patent/US20240358720A1/en active Pending
- 2022-08-30 IL IL309246A patent/IL309246A/en unknown
- 2022-08-30 WO PCT/IB2022/058130 patent/WO2023031798A1/en not_active Ceased
- 2022-08-30 CN CN202280057415.5A patent/CN117835977A/zh active Pending
- 2022-08-30 MX MX2024002566A patent/MX2024002566A/es unknown
- 2022-08-30 CA CA3225444A patent/CA3225444A1/en active Pending
- 2022-08-30 EP EP22772596.7A patent/EP4395768A1/en active Pending
- 2022-08-30 KR KR1020247009905A patent/KR20240055021A/ko active Pending
- 2022-08-30 JP JP2024512986A patent/JP2024532325A/ja active Pending
- 2022-08-30 AU AU2022340987A patent/AU2022340987A1/en active Pending
- 2022-09-01 TW TW111133168A patent/TW202327579A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240358720A1 (en) | 2024-10-31 |
| MX2024002566A (es) | 2024-03-20 |
| EP4395768A1 (en) | 2024-07-10 |
| JP2024532325A (ja) | 2024-09-05 |
| WO2023031798A1 (en) | 2023-03-09 |
| KR20240055021A (ko) | 2024-04-26 |
| CN117835977A (zh) | 2024-04-05 |
| AU2022340987A1 (en) | 2024-01-18 |
| CA3225444A1 (en) | 2023-03-09 |
| TW202327579A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290006A (en) | Dosing regimen for an IDO inhibitor | |
| IL289949A (en) | Dosing regimens for oral complement factor d inhibitors | |
| PT4340842T (pt) | Sotorasib para utilização no tratamento de cancro | |
| IL309246A (en) | Dosage regimen for TEAD inhibitor | |
| PT4058148T (pt) | Regime de dosagem para agentes anti-bcma | |
| PT4323338T (pt) | Inibidores de tead | |
| HK40109528A (en) | Dosing regimen for a tead inhibitor | |
| GB202011616D0 (en) | A Package | |
| IL315178A (en) | Dosage regimen | |
| GB202006819D0 (en) | Dosage regimen | |
| HK40076620A (en) | A dosing regimen for an ido inhibitor | |
| GB2598910B (en) | A workstation | |
| GB202209285D0 (en) | Dosage regimen for AXL inhibitor | |
| GB202208131D0 (en) | Dosage regimen for AXL inhibitor | |
| HK40116355A (en) | Complement inhibitor dosing regimens | |
| CA3288129A1 (en) | A dosing regimen | |
| HK40131582A (en) | A dosing regimen | |
| AU2023900983A0 (en) | A dosing regimen | |
| GB202319534D0 (en) | Dosage regimen | |
| GB202306662D0 (en) | Dosage regimen | |
| GB202015771D0 (en) | Dosage regimen | |
| GB202014116D0 (en) | Dosage regimen | |
| GB202006699D0 (en) | Dosage regimen | |
| HK40081443A (en) | Dosing regimens for a protein kinase c inhibitor | |
| GB202408767D0 (en) | a package |